Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

1α,25(OH)2-vitamin D3 increases dysferlin expression in vitro and in a human clinical trial

  • Luna, Noemí de
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Paradas, Carmen|||0000-0002-6917-2236
  • Iturriaga, Cristina
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Araque, Josefa
  • Genebriera, Mireia
  • Gich, Ignasi|||0000-0003-3975-6588
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
Dysferlinopathies are a heterogenous group of autosomal recessive inherited muscular dystrophies caused by mutations in DYSF gene. Dysferlin is expressed mainly in skeletal muscle and in monocytes and patients display a severe reduction or absence of protein in both tissues. Vitamin D3 promotes differentiation of the promyelocytic leukemia HL60 cells. We analyzed the effect of vitamin D3 on dysferlin expression in vitro using HL60 cells, monocytes and myotubes from controls and carriers of a single mutation in DYSF. We also performed an observational study with oral vitamin D3 in a cohort of 21 carriers. Fifteen subjects were treated for 1 year and dysferlin expression in monocytes was analysed before and after treatment. Treatment with vitamin D3 increased expression of dysferlin in vitro. The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Carriers treated with vitamin D3 had significantly increased expression of dysferlin in monocytes compared with nontreated carriers (P 0.05). These findings will have important therapeutic implications since a combination of different molecular strategies together with vitamin D3 uptake could increase dysferlin expression to nonpathological protein levels. © The American Society of Gene & Cell Therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Dysferlin Expression in Human Skeletal Muscle with That in Monocytes for the Diagnosis of Dysferlin Myopathy

  • Gallardo, Eduard|||0000-0002-3942-3436
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Flix, Bàrbara|||0000-0002-4731-7801
  • de Morrée, Antoine
  • van der Maarel, Silvère
  • Illa, Isabel|||0000-0002-2186-2684
Dysferlinopathies are caused by mutations in the dysferlin gene (DYSF). Diagnosis is complex due to the high clinical variability of the disease and because dysferlin expression in the muscle biopsy may be secondarily reduced due to a primary defect in some other gene. Dysferlin is also expressed in peripheral blood monocytes (PBM). Studying dysferlin in monocytes is used for the diagnosis of dysferlin myopathies. The aim of the study was to determine whether dysferlin expression in PBM correlates with that in skeletal muscle. Using western-blot (WB) we quantified dysferlin expression in PBM from 21 pathological controls with other myopathies in whom mutations in DYSF were excluded and from 17 patients who had dysferlinopathy and two mutations in DYSF. Results were compared with protein expression in muscle by WB and immunohistochemistry (IH). We found a good correlation between skeletal muscle and monocytes using WB. However, IH results were misleading because abnormal expression of dysferlin was also observed in 13/21 pathological controls. The analysis of dysferlin protein expression in PBM is helpful when: 1) the skeletal muscle IH pattern is abnormal or 2) when muscle WB can not be performed either because muscle sample is lacking or insufficient or because the muscle biopsy is taken from a muscle at an end-stage and it mainly consists of fat and fibrotic tissue.